← Back to Screener
Veracyte, Inc. (VCYT)
Price$33.03
Favorite Metrics
Price vs S&P 500 (26W)-7.01%
Price vs S&P 500 (4W)-3.54%
Market Capitalization$2.66B
P/E Ratio (Annual)40.04x
All Metrics
P/CF (Annual)19.49x
Book Value / Share (Quarterly)$16.50
P/TBV (Annual)2.73x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)20.37%
Cash Flow / Share (Quarterly)$1.60
Price vs S&P 500 (YTD)-21.79%
Gross Margin (TTM)70.10%
Net Profit Margin (TTM)12.83%
EPS (TTM)$0.81
10-Day Avg Trading Volume0.64M
EPS Excl Extra (TTM)$0.81
Revenue Growth (5Y)34.50%
EPS (Annual)$0.82
ROI (Annual)5.07%
Gross Margin (Annual)70.10%
Net Profit Margin (5Y Avg)-9.83%
Cash / Share (Quarterly)$5.20
P/E Basic Excl Extra (TTM)40.04x
Revenue Growth QoQ (YoY)18.55%
P/E Normalized (Annual)40.04x
ROA (Last FY)4.72%
Revenue Growth TTM (YoY)16.01%
EBITD / Share (TTM)$0.74
ROE (5Y Avg)-2.06%
Operating Margin (TTM)11.17%
Cash Flow / Share (Annual)$1.60
P/B Ratio2.03x
P/B Ratio (Quarterly)2.54x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)4.44x
Net Interest Coverage (TTM)-67.00x
ROA (TTM)4.88%
EPS Growth QoQ (YoY)690.97%
EV / EBITDA (TTM)38.62x
EPS Incl Extra (Annual)$0.82
Current Ratio (Annual)8.15x
Quick Ratio (Quarterly)7.63x
3-Month Avg Trading Volume0.86M
52-Week Price Return5.91%
EV / Free Cash Flow (Annual)18.12x
P/E Incl Extra (TTM)40.04x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$15.38
P/S Ratio (Annual)5.14x
Asset Turnover (Annual)0.37x
52-Week High$50.71
Operating Margin (5Y Avg)-12.03%
EPS Excl Extra (Annual)$0.82
CapEx CAGR (5Y)27.79%
Tangible BV CAGR (5Y)27.56%
26-Week Price Return-3.02%
Quick Ratio (Annual)7.63x
13-Week Price Return-21.66%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)8.15x
Enterprise Value$2,294.512
Revenue / Share Growth (5Y)23.78%
Asset Turnover (TTM)0.38x
Book Value / Share Growth (5Y)17.92%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)7.31x
Pretax Margin (Annual)13.19%
Cash / Share (Annual)$5.20
3-Month Return Std Dev47.92%
Gross Margin (5Y Avg)67.52%
Net Income / Employee (TTM)$0
ROE (Last FY)5.07%
Net Interest Coverage (Annual)-75.72x
EPS Basic Excl Extra (Annual)$0.82
P/FCF (TTM)20.98x
Receivables Turnover (TTM)11.34x
EV / Free Cash Flow (TTM)18.12x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.81
Receivables Turnover (Annual)11.34x
ROI (TTM)5.33%
P/S Ratio (TTM)5.14x
Pretax Margin (5Y Avg)-10.34%
Revenue / Share (Annual)$6.42
Tangible BV / Share (Annual)$15.38
Forward P/E19.91x
Price vs S&P 500 (52W)-23.92%
P/E Ratio (TTM)40.04x
EPS Growth TTM (YoY)167.29%
Year-to-Date Return-19.14%
5-Day Price Return8.58%
EPS Normalized (Annual)$0.82
ROA (5Y Avg)-1.92%
Net Profit Margin (Annual)12.83%
Month-to-Date Return5.68%
Cash Flow / Share (TTM)$-0.31
EBITD / Share (Annual)$0.74
Operating Margin (Annual)11.17%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)19.49x
ROI (5Y Avg)-2.06%
P/E Excl Extra (TTM)40.04x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$0.81
P/TBV (Quarterly)2.73x
P/B Ratio (Annual)2.54x
Inventory Turnover (TTM)7.27x
Pretax Margin (TTM)13.19%
Book Value / Share (Annual)$16.50
Price vs S&P 500 (13W)-22.34%
Beta1.99x
P/FCF (Annual)20.98x
Revenue / Share (TTM)$6.27
ROE (TTM)5.33%
52-Week Low$22.61
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Health Services(20)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
VCYTVeracyte, Inc. | 40.04x | 16.01% | 11.17% | 5.33% | $33.03 |
NTRANatera, Inc. Common Stock | — | 35.90% | -13.44% | -15.28% | $196.11 |
LHLabcorp Holdings Inc. | 25.08x | 7.25% | 9.92% | 10.28% | $266.36 |
DGXQuest Diagnostics Inc. | 21.24x | 11.78% | 14.10% | 13.88% | $191.46 |
EXASExact Sciences Corp | — | 17.69% | -6.35% | -8.51% | $104.91 |
GHGuardant Health, Inc. Common Stock | — | 32.88% | -45.02% | -246.60% | $85.70 |
RDNTRadNet, Inc. Common Stock | 1779.27x | 11.51% | 3.04% | -1.88% | $60.09 |
GRALGRAIL, Inc. Common Stock | — | 17.18% | -381.98% | -17.11% | $49.47 |
CDNACareDx, Inc. | 18.34x | 13.79% | -8.10% | -6.47% | $22.42 |
FTREFortrea Holdings Inc. Common Stock | — | 1.00% | -32.04% | -152.17% | $10.09 |
CSTLCastle Biosciences, Inc. Common Stock | 47.31x | 3.66% | -12.44% | -5.27% | $24.56 |
About
Veracyte is a genomic diagnostics company providing molecular tests to help clinicians diagnose and treat cancer across multiple tumor types. Its portfolio includes Decipher tests for prostate and bladder cancer, Afirma for thyroid cancer, and Prosigna for breast cancer. These precision diagnostics enable informed clinical decision-making and improve patient outcomes at critical treatment junctures.